Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-08-21
2007-08-21
Foley, Shanon (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024310
Reexamination Certificate
active
10895545
ABSTRACT:
The invention concerns composititions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.
REFERENCES:
patent: 4339441 (1982-07-01), Kalman et al.
patent: 4474893 (1984-10-01), Reading
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 4900811 (1990-02-01), Sutcliffe
patent: 4923696 (1990-05-01), Appel et al.
patent: 5017375 (1991-05-01), Appel et al.
patent: 5141856 (1992-08-01), Collins et al.
patent: 5166317 (1992-11-01), Wallace et al.
patent: 5202428 (1993-04-01), Schubert
patent: 5206007 (1993-04-01), Ooshima et al.
patent: 5210026 (1993-05-01), Kovesdi et al.
patent: 5214031 (1993-05-01), Uchida
patent: 5215969 (1993-06-01), Springer et al.
patent: 5218094 (1993-06-01), della Valle
patent: 5242798 (1993-09-01), Sutcliffe
patent: 5250414 (1993-10-01), Schwab et al.
patent: 5284932 (1994-02-01), Sen
patent: 5534615 (1996-07-01), Baker et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571675 (1996-11-01), Baker et al.
patent: 5571893 (1996-11-01), Baker et al.
patent: 5624806 (1997-04-01), Baker et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5627073 (1997-05-01), Baker et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5679545 (1997-10-01), Baker et al.
patent: 6046035 (2000-04-01), Shi et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: 6324479 (2001-11-01), Friend
patent: 233838 (1987-08-01), None
patent: 474979 (1992-03-01), None
patent: 476933 (1992-03-01), None
patent: 55-020721 (1980-02-01), None
patent: 4169600 (1992-06-01), None
patent: WO90/09399 (1990-08-01), None
patent: WO92/11026 (1992-07-01), None
patent: WO92/18140 (1992-10-01), None
patent: WO92/20797 (1992-11-01), None
patent: WO92/22665 (1992-12-01), None
patent: WO93/03758 (1993-03-01), None
patent: WO93/06116 (1993-04-01), None
patent: WO93/07270 (1993-04-01), None
patent: WO93/18065 (1993-09-01), None
patent: WO93/18186 (1993-09-01), None
patent: WO93/24529 (1993-12-01), None
patent: WO94/05788 (1994-03-01), None
patent: WO97/30146 (1997-08-01), None
patent: WO99/00415 (1999-01-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Krystal et al (Molecular and Cellular Biology, 1988, 8(8):3373-3381).
Wollert et al (J Mol Med, 1997, 75:492-501).
Acland et al., “Subcellular fate of the Int-2 oncoprotein is determined by choice of initiation codon”Nature343:662-665 (1990).
Alberts, et alMolecular Biology of the Cell, 3rd edition edition pp. 465 (1994).
Alitalo and Schwab, “Oncogene amplification in tumor cells”Advances in Cancer Research47:235-281 (1986).
Barton, “Protein sequence alignment and database scanning”Protein Structure Predictionpp. 31-63 (1996).
Bazan, J.F., “Neuropoietic Cytokines in the Hematopoietic Fold”Neuron7:197-208 (Aug. 1991).
Boheler et al., “Gene Expression in Cardiac Hypertrophy”TCM2 (5) : 176-182 (1992).
Bradley et al., “Modifying the mouse: design and desire”Bio Technology10:534-539 (1992).
Burgess et at., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (1990).
Chatterjee et al., “Idiotypic antibody immunotherapy of cancer”Immunotherapy38:75-82 (1994).
Chen et al., “Pharmacological Characterization of the Activity of Endogenous Inotropic Factor from Porcine Left Ventricle”J. Cardiovas. Pharmacol. 22 (Suppl. 2) :S93-S95 (1993).
Chien et al., “Regulation of Cardiac Gene Expression During Myocardial Growth and Hypertrophy: Molecular Studies of an Adaptive Physiologic Response”FASEB Journal5:3037-3046 (1991).
Chien et al., “Transcriptional Regulation During Cardiac Growth and Development”Annu. Rev. Physiol. 55:77-95 (1993)..
Chien, K.R., “Molecular Advances in Cardiovascular Biology”Science260(5110) :916-917 (May 14, 1993).
Davis et al., “The Molecular Biology of the CNTF Receptor”Current Opinion in Cell Biology5:281-285 (1993).
Dermer, G., “Another anniversary for the war on cancer”Biotechnology12:320 (1994).
Fassler et al., “Knockout Mice: How to Make Them and Why. The Immunological Approach”Int. ARch Allergy Immunol. 106:323-334 (1995).
Fishwild et al., “High-Avidity Human IgGκ Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice”Nature Biotechnology. 14 (7) :845-851 (Jul. 1996).
Frelin, “Serum Growth Factors for Rat Cardiac Non-Muscle Cells in Culture”J. Molec. and Cell. Cardiol. 12:1329-1340 (1980).
Fu et alEMBO Journal15:4392-4401 (1996).
Fu et al.EMBO Journal15:4392-4401 (1996).
Gelmini et al., “Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification”Clinical Chemistry43 (5) :752-758 (May 1997).
George et al., “Current Methods in Sequence Comparison and Analysis”Macromolecular Sequencing and Synthesispp. 127-149 (1988).
Gray et al., “Fluorescence in situ hybridization in cancer and radiation biology”Radiation Research137(3) :275-289 (Mar. 1994).
Grimm et al., “Ventricular Nucleic Acid and Protein Levels with Myocardial Growth and Hypertrophy”Circ. Res. XIX:552-558 (1966).
Gura, T., “Systems for identifying new drugs are often faulty”Science278 (5340) :1041-1042 (Nov. 7, 1997).
Iwaki et al., “α- and β-Adrenergic Stimulation Induces Distinct Patterns of Immediate Early Gene Expression in Neonatal Rat Myocardial Cells”Journal of Biological Chemistry265(23) :13809-13817 (Aug. 15, 1990).
Jain, R., “Barriers to drug delivery in solid tumors”Scientific American271(1) :58-65 (Jul. 1994).
Jones et al., “Association Between Inhibition of Arachidonic Adic Release and Prevention of Calcium Loading During ATP Depletion in Cultured Rat Cardiac Myocytes”American Journal of Pathology135(3) :541-556 (1989).
Kanda et al., “An Interleukin-6 Secreting Myxoma in a Hypertrophic Left Ventricle”Chest105(3) :962-963 (1994).
Karasik et al, “Growth Factors Identified in Myocardium of Patients with Hypertrophic Cardiomyopathy”JACC(abstract) 13(2) :118A (1989).
Kishimoto et al., “Cytokine Signal Transduction”Cell76:253-262 (Jan. 28, 1994).
Kitamura et al., “Multimeric Cytokine Receptors”Trends Endocrinol. Metabol. 5(1) :8-14 (1994).
Knowlton et al., “Co-Regulation of the Atrial Natriuretic Factor and Cardiac Myosin Light Chain-2 Genes During α-Adrenergic Stimulation of Neonatal Rat Ventricular Cells”Journal of Biological Chemistry266(12) :7759-7768 (Apr. 25, 1991).
Knowlton et al., “α1a-Adrenergic Receptor Subtype Mediates Biochemical, Molecular, and Morphologic Features of Cultured Myocardial Cell Hypertrophy”Journal of Biological Chemistry268 (21) :15374-15380 (Jul. 25, 1993).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”Molecular&Cellular Biology8 (3) :1247-1252 (Mar. 1988).
Lee et al., “Atrial Natriuretic Factor Gene Expression in Ventricles of Rats with Spontaneous Biventricular Hypertrophy”J. Clin. Inve
Botstein David
Goddard Audrey
Lawrence David A.
Pennica Diane
Roy Margaret Ann
Aeder Sean
Foley Shanon
Genentech Inc.
LandOfFree
Cardiotrophin-1 compositions and methods for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiotrophin-1 compositions and methods for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiotrophin-1 compositions and methods for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840299